Welcome to our dedicated page for Delcath Sys news (Ticker: DCTH), a resource for investors and traders seeking the latest updates and insights on Delcath Sys stock.
The Delcath Systems Inc (DCTH) news page on Stock Titan aggregates company announcements, clinical updates, and financial disclosures for this interventional oncology business focused on primary and metastatic liver cancers. Delcath’s communications frequently highlight developments related to its proprietary hepatic delivery technologies, HEPZATO KIT and the CHEMOSAT Hepatic Delivery System for Melphalan, which are used in percutaneous hepatic perfusion (PHP) procedures.
Investors and observers can use this news feed to follow earnings reports and financial updates, including quarterly and preliminary revenue results, product revenue from HEPZATO KIT in the United States and CHEMOSAT in Europe, gross margin commentary, and discussions of non-GAAP measures such as adjusted EBITDA. The company also issues releases on capital allocation and corporate actions, such as authorization of share repurchase programs and equity inducement grants under stock incentive plans.
A significant portion of Delcath’s news flow centers on clinical and scientific developments. Recent announcements describe subgroup analyses from the Phase 3 FOCUS study of Melphalan/Hepatic Delivery System in unresectable metastatic uveal melanoma, the Phase 2 CHOPIN trial evaluating CHEMOSAT with ipilimumab and nivolumab, real-world evidence from retrospective analyses of metastatic uveal melanoma patients, and a 10-year single-center experience with CHEMOSAT in liver-dominant disease. The company also highlights expert narrative reviews discussing PHP with melphalan using HEPZATO KIT, including patient selection, technique, and outcomes.
Additional updates include participation in investor conferences and scheduling of earnings calls, providing context for how Delcath communicates with the capital markets. For users tracking DCTH, this page offers a centralized view of regulatory, clinical, and financial news that shapes the company’s progress in liver-directed oncology therapies. Bookmark this feed to monitor new data releases, product-related publications, and ongoing disclosures from Delcath Systems Inc.
Delcath Systems, Inc. (Nasdaq: DCTH) announced the acceptance of a poster presentation for the FOCUS Phase 3 Trial results at the upcoming ASCO 2022 Annual Meeting in Chicago, running from June 3-7, 2022. The session will focus on the use of Percutaneous Hepatic Perfusion (PHP) with Melphalan in patients with liver metastases from ocular melanoma. The presentation, led by Dr. Jonathan Zager, is scheduled for June 6, 2022.
Delcath's PHP system is designed for targeted high-dose chemotherapy delivery to the liver, addressing unresectable hepatic-dominant metastatic ocular melanoma.
Delcath Systems, a leader in interventional oncology, announced a conference call to discuss its Q1 2022 financial results. The event is scheduled for May 10, 2022, at 8:30 AM ET. Participants can join by dialing in or via webcast. Delcath’s proprietary PHP system delivers high-dose chemotherapy specifically for liver cancers, including metastatic ocular melanoma, under the brand names HEPZATO in the U.S. and CHEMOSAT in Europe. This innovative approach minimizes systemic exposure while targeting cancer effectively, highlighting the company's commitment to advancing cancer treatment.
Delcath Systems, traded as DCTH, will participate in the Canaccord Genuity Horizons in Oncology Conference on April 14, 2022, at 3:00 PM ET. The event will feature a fireside chat and management will engage in virtual one-on-one meetings. Delcath focuses on treating liver cancers using its proprietary percutaneous hepatic perfusion (PHP) system, currently under development in the U.S. as HEPZATO KIT for metastatic ocular melanoma. In Europe, the PHP system is approved as CHEMOSAT to treat various liver cancers.
Delcath Systems, focused on interventional oncology, will participate in the Lytham Partners Spring 2022 Investor Conference. Key events include a presentation on April 4, 2022, at 11:00am ET, and a panel discussion on April 5, 2022, at 2:00pm ET, addressing technologies in cancer treatment. The company is known for its proprietary percutaneous hepatic perfusion system aimed at treating liver cancers, notably under the names HEPZATO in the U.S. and CHEMOSAT in Europe.
Delcath Systems reported its business highlights and financial results for Q4 and full-year 2021 on March 25, 2022. The company updated positive Phase 3 trial results for the HEPZATO Kit, confirmed a mid-year NDA resubmission to the FDA, and resumed sales of CHEMOSAT in Europe. Q4 product revenue was approximately $0.2 million, with a net loss of $5.3 million, an improvement from Q4 2020. For the year, product revenue totaled $1.3 million, while the net loss increased to $25.6 million. As of December 31, 2021, cash and equivalents totaled $27 million.
Delcath Systems (Nasdaq: DCTH) will host a conference call on March 25, 2022, at 8:30 AM ET, to discuss fourth quarter and full year results for 2021. Participation is available via phone or online. The webcast link provides additional access for investors globally.
Delcath specializes in interventional oncology, focusing on liver cancers. Their proprietary PHP system delivers high-dose chemotherapy with minimal systemic exposure, and is known as HEPZATO KIT in the U.S. and CHEMOSAT in Europe.
Delcath Systems, Inc. (DCTH) will present at the 34th annual Roth Conference on March 14, 2022, at 3:30 PM PT. The presentation focuses on the company's innovative treatment for liver cancers, specifically the percutaneous hepatic perfusion (PHP) system, known as HEPZATO in the U.S. for metastatic ocular melanoma. In Europe, this system is marketed as CHEMOSAT. A webcast of the presentation will be available online. For further inquiries or one-on-one meetings, interested parties are encouraged to contact Delcath's investor relations.
Delcath Systems, Inc. (Nasdaq: DCTH) announced that its CHEMOSAT Hepatic Delivery System received certification under the new EU Medical Device Regulation (MDR) as of February 28, 2022. This transition from Class IIb to Class III signifies enhanced scrutiny, requiring more evidence on safety and performance. CHEMOSAT had previously been certified under the Medical Device Directive since 2012. The MDR ensures greater oversight, including post-marketing surveillance and unique device identification. The device is utilized for treating various liver cancers in major medical centers.
Delcath Systems, Inc. (Nasdaq: DCTH) announced its decision to resume direct responsibility for the sales, marketing, and distribution of the CHEMOSAT® Hepatic Delivery System in Europe effective March 1, 2022. This move comes after medac GmbH held the license for the product since December 2018. Delcath aims for a smooth transition to ensure patient access to CHEMOSAT, a proprietary device that delivers high-dose chemotherapy to the liver while managing systemic exposure. The product has been used in major medical centers for treating liver cancers since its EU launch in 2012.
Delcath Systems (Nasdaq: DCTH) announced its participation in two upcoming virtual investor conferences. The first is the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 17, 2022, at 11:00 AM ET, which will not be webcast. The second event is the 2022 SVB Leerink Global Healthcare Conference on February 18, 2022, at 9:20 AM ET, which will be available via webcast. Delcath focuses on interventional oncology, particularly using its proprietary PHP system for treating liver cancers.